ArticleCell2017
KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.
Open access · bronzeAbstract readComment
In one paragraph
Article in Cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 121 papers.
0numbers the graph read from it
0cells of the map it votes in
121citing papers in PubMed
10.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
121 citing papers in PubMed, 183 citations in OpenAlex.
- Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia.Clinical lymphoma, myeloma & leukemia · 2019Trial
- Targeting Oncogenic KRAS Using Peptide Nucleic Acid Oligomers Attached to Cell-Penetrating Peptides.International journal of molecular sciences · 2026Article
- Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.Blood advances · 2026Article
- Article
- Online tutorial on survival analysis for biomarker discovery.PLoS computational biology · 2026Article
- The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations.EMBO molecular medicine · 2025Article
- Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.British journal of cancer · 2025Article
- A first-in-class EGFR-directed KRAS G12V selective inhibitor.Cancer cell · 2025Article
- The rise of RAS: how gradual oncogene activation shapes the OIS spectrum.Genes & development · 2025Review
- Elucidating Ras protein as a dual therapeutic target for inflammation and cancer: a review.Discover oncology · 2025Review
- Unlocking the Genetic Secrets of Pancreatic Cancer:Cancers · 2025Review
- Article
- KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition.Cancer research · 2025Article
- Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia.Molecular cancer therapeutics · 2025Review
- RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade.Nature communications · 2024Article
- MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer.Signal transduction and targeted therapy · 2024Review
- Review
- Copy number losses of oncogenes and gains of tumor suppressor genes generate common driver mutations.Nature communications · 2024Article
- Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance.Current oncology (Toronto, Ont.) · 2024Review
61 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Comment on
Authors and funding
22 authors at 7 institutions in 1 country.
Michael R BurgessDepartment of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Eugene HwangDepartment of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA.
Rana MroueDepartment of Discovery Oncology, Genentech, South San Francisco, CA 94080, USA.
Craig M BielskiMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Anica M WandlerDepartment of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA.
Benjamin J HuangDepartment of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA.
Ari J FirestoneDepartment of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA.
Amy YoungDepartment of Translational Oncology, Genentech, South San Francisco, CA 94080, USA.
Jennifer A LacapDepartment of Translational Oncology, Genentech, South San Francisco, CA 94080, USA.
Lisa CrockerDepartment of Translational Oncology, Genentech, South San Francisco, CA 94080, USA.
Saurabh AsthanaDepartment of Medicine, University of California San Francisco, San Francisco, CA 94143, USA.
Elizabeth M DavisSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Jin XuDepartment of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA.
Keiko AkagiDepartment of Cancer Biology and Genetics, Ohio State University, Columbus, OH 43210, USA.
Michelle M Le BeauSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA.
Qing LiDivision of Hematology/Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI 48109, USA.
Benjamin HaleyDepartment of Molecular Biology, Genentech, South San Francisco, CA 94080, USA.
David StokoeDepartment of Discovery Oncology, Genentech, South San Francisco, CA 94080, USA.
Deepak SampathDepartment of Translational Oncology, Genentech, South San Francisco, CA 94080, USA.
Barry S TaylorMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Marie EvangelistaDepartment of Discovery Oncology, Genentech, South San Francisco, CA 94080, USA. Electronic address: evangelista.marie@gene.com.
Kevin ShannonDepartment of Pediatrics, University of California San Francisco, San Francisco, CA 94143, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA. Electronic address: kevin.shannon@ucsf.edu.
University of California, San Francisco · USUniversity of Chicago · USMemorial Sloan Kettering Cancer Center · USMolecular Oncology (United States) · USThe Ohio State University · USUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of Michigan–Ann Arbor · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MMolecular and Cellular Mechanisms in CancerT32CA108462 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2004 to 2024
$10.4MMSKCC Pilot Center for Precision Disease ModelingU54OD020355 · OD · SLOAN-KETTERING INST CAN RESEARCH · PI LOWE, SCOTT W., SOLIT, DAVID B. · 2015 to 2019
$9.9MResearch Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0MTranslational Investigation of KRas & NF1 in Myeloid LeukemiaR37CA072614 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHANNON, KEVIN M. · 2007 to 2016
$3.4MTranslational Investigation of NF1 in Myeloid LuekemiaR01CA072614 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHANNON, KEVIN M. · 1997 to 2006
$2.0MUnderstanding Long Tail Driver Mutations in CancerR01CA204749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHULTZ, NIKOLAUS · 2017 to 2021
$2.0MTargeting AKT-Mutant Human CancersR01CA207244 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SOLIT, DAVID B. · 2016 to 2020
$2.0M(PQD1) Response and Resistance to Inhibitors of Ras Effectors in Blood CancersR01CA180037 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHANNON, KEVIN M. · 2013 to 2016
$1.3MNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA072614NCI NIH HHS R01 CA180037NCI NIH HHS R01 CA204749NCI NIH HHS R01 CA207244NCI NIH HHS R37 CA072614NCI NIH HHS T32 CA108462NCI NIH HHS T32 CA128583NIH HHS U54 OD020355
Abstract
Investigating therapeutic "outliers" that show exceptional responses to anti-cancer treatment can uncover biomarkers of drug sensitivity. We performed preclinical trials investigating primary murine acute myeloid leukemias (AMLs) generated by retroviral insertional mutagenesis in Kras
Indexed as
MAP Kinase Signaling SystemAnimalsAntineoplastic AgentsBenzamidesCell Line, TumorClonal EvolutionColorectal NeoplasmsDiphenylamineDrug Resistance, NeoplasmHumansLeukemia, Myeloid, AcuteMiceMutationProto-Oncogene Proteins p21(ras)RetroviridaeAntineoplastic AgentsBenzamidesDiphenylamineKRAS protein, humanmirdametinibProto-Oncogene Proteins p21(ras)allelic imbalanceAMLcolorectal cancerdrug resistanceKRASMEK inhibition
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.